HRS-8080

Phase 2Small molecule

SShandong Suncadia Medicine Co., Ltd.

HRS-8080 is one of 76 small molecule programs targeting Breast Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerNot yet recruiting

RandomizedNot yet recruiting

FemaleNot yet recruiting

Breast CancerPhase 2

Not yet recruiting

RandomizedPhase 1

Not yet recruiting

FemalePhase 1

Not yet recruiting

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

HRS-8080

SShandong Suncadia Medicine Co., Ltd.

Phase 2

5 2

Adenocard

Astellas

Preclinical

2 3

Lexiscan

Astellas

Preclinical

1 4

Tianeptine

Pfizer

Preclinical

1 5

Ablavar

LLantheus Medical Imaging

Preclinical

2 6

Diuretic

RReprieve Cardiovascular, Inc

Preclinical

1 7

Recombinant Human Endostatin

PPeking University Third Hospital

Preclinical

1 8

Naltrexone/bupropion

Novo Nordisk

Preclinical

1 9

Sertraline ODT

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 10

Tc99m Sestamibi

MM.D. Anderson Cancer Center

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1/2Recruiting

Breast Cancer

NCT06679036

Q4 2027

Phase 3Recruiting

Breast Cancer

NCT07024173

Q1 2028

Phase 2Not yet recruiting

Breast Cancer

NCT07125950

Q4 2028

Phase 1/2Not yet recruiting

Breast Cancer

NCT07389733

Clinical

Trials by Indication[1]

Breast Cancer5 trials

SHR2554 Combined With Endocrine Therapy in Advanced Breast Cancer

Not yet recruiting·HHenan Cancer Hospital·Phase 2·NCT07125950·60 enrolled

A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer

Recruiting·SShandong Suncadia Medicine Co., Ltd.·Phase 3·NCT07024173·240 enrolled

A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With High-Risk Early Breast Cancer

Recruiting·SShandong Suncadia Medicine Co., Ltd.·Phase 3·NCT07349069·4,800 enrolled

Show 2 more trials

A Trial of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Breast Cancer Patients

Recruiting·SShandong Suncadia Medicine Co., Ltd.·Phase 1/2·NCT06679036·300 enrolled

A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer

Not yet recruiting·SShandong Suncadia Medicine Co., Ltd.·Phase 1/2·NCT07389733·180 enrolled

Randomized1 trial

A Phase 1, Randomized, Crossover Study to Evaluate the Relative Bioavailability and Food Effect of HRS-8080 in Healthy Subjects

Not yet recruiting·SShandong Suncadia Medicine Co., Ltd.·Phase 1·NCT06619873·24 enrolled

Female1 trial

A Study to Assess the Mass Balance of [14C]HRS-8080 in Healthy Chinese Postmenopausal Female Subjects.

Not yet recruiting·SShandong Suncadia Medicine Co., Ltd.·Phase 1·NCT07320521·6 enrolled

Trial1 trial

A Trial of Itraconazole Effect on HRS-8080 Pharmacokinetics in Healthy Participants

Completed·SShandong Suncadia Medicine Co., Ltd.·Phase 1·NCT07229560·16 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for HRS-8080. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HRS-8080 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HRS-8080. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shandong Suncadia Medicine Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SShandong Suncadia Medicine Co., Ltd.

HRS-8080

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2027

Q1 2028

Q4 2028

Trials by Indication[1]

Breast Cancer5 trials

Randomized1 trial

Female1 trial

Trial1 trial

References

Drug Info

Quick Facts

Related News